biotech
Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $10 Billion Collaboration for Rare Disease Treatments
Sarepta Therapeutics, Arrowhead Pharmaceuticals, RNAi, Rare Diseases, Genetic Medicine, Collaboration Agreement, Biotech, Pharmaceutical Industry
Metsera Secures $215M to Accelerate Obesity Drug Development
Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease
Insights from Jade CEO: Reverse Merger and IgAN Drug Development
Jade CEO, Reverse Merger, IgAN Drugs, Pharmaceutical Development, Biotech Mergers
Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion
Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition
Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody
Ottimo Pharma, David Epstein, PD1/VEGFR2 bi-functional antibody, Cancer immunotherapy, VEGF bifunctional antibody, Biotech startup
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy
AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation
Lundbeck Strengthens Neuro-Rare Disease Portfolio with $2.6 Billion Acquisition of Longboard Pharmaceuticals
Lundbeck, Longboard Pharmaceuticals, Neuro-Rare Diseases, Acquisition, Biotech, Pharmaceutical Industry
Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation
Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment
Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine
Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships